AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30642372
Drug: Chiauranib 65
RxNorm normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiauranib 65 mg/day
Trial: 30642372
Drug: Chiauranib 50
RxNorm normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiauranib 50 mg/day
Trial: 30642372
Drug: Chiauranib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiauranib (various doses from 10 to 65 mg/day)
Trial: 30642373
Drug: JS001 (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 (anti-PD-1 antibody)
Trial: 30642415
Drug: Amisulpride (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (6 weeks treatment)
Trial: 30642537
Drug: Afatinib (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (first-line treatment, modified starting dose of ≤30 mg for 31.1% of patients, 40 mg starting dose for others)
Trial: 30642537
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg starting dose)
Trial: 30642819
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg or 560 mg daily) + Nivolumab (3 mg/kg every 2 weeks)
Trial: 30643112
Drug: Pressurized intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin 92 mg/m² or cisplatin 7.5 mg/m² and doxorubicin 1.5 mg/m², repeated every 6 weeks
Trial: 30644585
Drug: Cangrelor as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor as a bridge therapy
Trial: 30644817
Drug: Focused ultrasound-mediated
RxNorm normalized name: carbinoxamine maleate Oral Solution [Pediatex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound-mediated hyperthermia for targeted drug delivery
Trial: 30648126
Drug: Dalbavancin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin (1500 mg IV on days 1 and 8)
Trial: 30648126
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4-6 weeks
Trial: 30648632
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/day individualized schedule
Trial: 30648932
Drug: PCV13 (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (first dose)
Trial: 30650259
Drug: Plazomicin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plazomicin (15 mg/kg administered by 30-minute intravenous infusion)
Trial: 30650259
Drug: Plazomicin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plazomicin (20 mg/kg administered by 30-minute intravenous infusion)
Trial: 30651126
Drug: Avelumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (10 mg/kg)
Trial: 30654137
Drug: Plerixafor (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (240 μg/kg s.c.) administered before conditioning chemotherapy (fludarabine and busulfan) for 1 to 4 days depending on the cohort.
Trial: 30656283
Drug: Prophylactic rFIXFc
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic rFIXFc with a ≥14-day dosing interval
Trial: 30656479
Drug: Pressure-volume curve-guided
RxNorm normalized name: Curae
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pressure-volume curve-guided PEEP titration
Trial: 30657223
Drug: Aflibercept (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (4 mg/kg) plus FOLFIRI administered every 2 weeks
Trial: 30657914
Drug: Dairy intake
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy intake (100 g/d increase)
Trial: 30657914
Drug: Fruit and
RxNorm normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit and vegetable intake (100 g/d increase)
Trial: 30657926
Drug: Plasma cotinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma cotinine (per 1 ng/mL)
Trial: 30658128
Drug: 9-valent HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent HPV vaccine
Trial: 30658992
Drug: Pediatric ALL
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pediatric ALL regimen administered by adult treatment teams
Trial: 30660511
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks up to four times)
Trial: 30660617
Drug: Grazoprevir 100
RxNorm normalized name: grazoprevir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg plus Elbasvir 50 mg (8 weeks treatment)
Trial: 30661177
Drug: Danvatirsen 3
RxNorm normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danvatirsen 3 mg/kg
Trial: 30661177
Drug: Danvatirsen 200
RxNorm normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danvatirsen 200 mg flat dosing
Trial: 30661177
Drug: Flat dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat dosing regimen
Trial: 30662958
Drug: Individual rewards
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual rewards for diabetes management, details on dosage and duration not available.
Trial: 30662958
Drug: Mixed rewards
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed rewards for diabetes management, details on dosage and duration not available.
Trial: 30664483
Drug: Ghya Bharari
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghya Bharari Ekatra intervention delivered in 6 weekly sessions by trained community educators; includes games, discussions, self-reflections, and skill-building exercises.
Trial: 30664496
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with TheraSphere yttrium-90 (TARE)
Trial: 30664564
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 1 g/kg/dose infused at 3-5, 30, and 60 days post-hepatoportoenterostomy (HPE)
Trial: 30667281
Drug: Evidence-based acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based acute treatments for ACS (including early dual antiplatelet therapy, heparins during hospitalization, reperfusion therapy for ST-segment-elevation myocardial infarction)
Trial: 30667281
Drug: Strategies for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies for secondary prevention (including dual antiplatelet therapy, ACE inhibitors/ARBs, statins at discharge, smoking cessation, cardiac rehabilitation counseling)
Trial: 30667348
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of anticoagulation therapy after endovascular thrombus removal and stent placement
Trial: 30668217
Drug: DTaP-IPV vaccine
RxNorm normalized name: DTaP-IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV vaccine
Trial: 30668843
Drug: Early therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early therapy (ET) - HIV-1-infected children
Trial: 30668843
Drug: Late therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late therapy (LT) - HIV-1-infected children
Trial: 30670069
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (72.3%)
Trial: 30670069
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (72.3%)
Trial: 30671005
Drug: Brief psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychological treatment based on Unified Protocol (UP)
Trial: 30671005
Drug: Conventional psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional psychological treatment
Trial: 30671005
Drug: Conventional psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional psychological treatment plus pharmacological treatment
Trial: 30671283
Drug: Mindfulness for
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness for Interdisciplinary HCPs (MIHP) - an 8-week, group-based course with weekly meditation training, gentle yoga, and discussions.
Trial: 30662958
Drug: Individual rewards
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual rewards for diabetes management, details on dosage and duration not available
Trial: 30662958
Drug: Mixed rewards
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed rewards for diabetes management, details on dosage and duration not available
Trial: 30672136
Drug: Oral sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral sirolimus
Trial: 30672141
Drug: PPI plus
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI plus histamine-2 (H2) blocker
Trial: 30672141
Drug: Control (H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (H2 blocker alone)
Trial: 30673992
Drug: Avaxim (Hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avaxim (Hepatitis A Virus Vaccine)
Trial: 30674731
Drug: 2 mg/d
RxNorm normalized name: Uceris, 2 mg/dose rectal foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/d oral nitisinone
Trial: 30674905
Drug: MR-guided focused
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy (liposomal doxorubicin or temozolomide)
Trial: 30674905
Drug: MR-guided focused
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy
Trial: 30675234
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, followed by maintenance therapy for non-progressors
Trial: 30675234
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, without maintenance therapy
Trial: 30678470
Drug: Insulin balanced
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin balanced infusion system (IBIS)
Trial: 30678753
Drug: Single-molecule counting
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-molecule counting high-sensitivity troponin I (hsTnI) with normal range <6 ng/l
Trial: 30679332
Drug: Perineural dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural dexmedetomidine (1 mL dexmedetomidine 100 µg/mL + 4 mL ropivacaine 5 mg/mL)
Trial: 30679332
Drug: Systemic dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic dexmedetomidine (1 mL saline + 4 mL ropivacaine 5 mg/mL)
Trial: 30679332
Drug: Control (NoDex:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (NoDex: 1 mL saline + 4 mL ropivacaine 7.5 mg/mL)
Trial: 30680407
Drug: Elbasvir 50
RxNorm normalized name: elbasvir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir 50 mg and Grazoprevir 100 mg once daily for 10 days
Trial: 30680712
Drug: PF-06647263 administered
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06647263 administered every week (QW)
Trial: 30680712
Drug: PF-06647263 administered
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06647263 administered every 3 weeks (Q3W)
Trial: 30680712
Drug: PF-06647263 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06647263 at the recommended phase 2 dose (RP2D) of 0.015 mg/kg QW
Trial: 30681551
Drug: CytoSorb treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoSorb treatment (2 consecutive 24-hour treatments)
Trial: 30681793
Drug: ATX-101 (deoxycholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 (deoxycholic acid injection)
Trial: 30681798
Drug: High-intensity precision
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity precision RF and fractional laser therapy
Trial: 30682081
Drug: Profile likelihood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profile likelihood based pointwise confidence intervals (CIs) for a nonlinear dose-response model.
Trial: 30682081
Drug: Profile likelihood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profile likelihood based pointwise confidence intervals (CIs) for nonlinear dose-response models.
Trial: 30683996
Drug: Previous immunisation
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous immunisation with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Trial: 30684076
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg daily for 24 weeks
Trial: 30684309
Drug: Glibenclamide oral
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide oral suspension
Trial: 30684505
Drug: Education-based intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education-based intensified insulin therapy (EBIIT)
Trial: 30685808
Drug: G-CSF-primed haplo-identical
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF-primed haplo-identical HSCT (Haplo-ID)
Trial: 30686583
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of oral cortisol (CORT)
Trial: 30686586
Drug: mAb114 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb114 5 mg/kg
Trial: 30686586
Drug: mAb114 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb114 25 mg/kg
Trial: 30686586
Drug: mAb114 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb114 50 mg/kg
Trial: 30686586
Drug: mAb114 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb114 (all doses)
Trial: 30686676
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of PLX-PAD cells
Trial: 30686756
Drug: Metformin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin added to abiraterone at 1000 mg twice daily in uninterrupted 4-week cycles
Trial: 30686767
Drug: Lumacaftor 100
RxNorm normalized name: lumacaftor 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 100 mg and ivacaftor 125 mg (bodyweight <14 kg) or lumacaftor 150 mg and ivacaftor 188 mg (bodyweight ≥14 kg) orally every 12 h for 15 days (part A) and for 24 weeks (part B)
Trial: 30687117
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no curry or lower doses)
Trial: 30687508
Drug: Invasive coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive coronary artery function-guided diagnosis and treatment
Trial: 30687508
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no invasive coronary artery function-guided diagnosis and treatment)
Trial: 30687714
Drug: Curcumin Phytosome
RxNorm normalized name: Jarrow Formulas Curcumin Phytosome Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin Phytosome (CP) 2 g/day for 2 weeks
Trial: 30687792
Drug: MVA85A vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine, details on dosage and duration not available
Trial: 30687970
Drug: IVIG 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 10% (1 g/kg daily)
Trial: 30688008
Drug: Raltegravir-based regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir-based regimen (protease-inhibitor-free)
Trial: 30688175
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and skills related to behavioral and psychological symptoms of dementia, disease expectations, safety, activities of daily living, medical care optimization, and medication utilization
Trial: 30689042
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg/day for 26 weeks (rasagiline-rasagiline group)
Trial: 30689042
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg/day for 26 weeks (placebo-rasagiline group)
Trial: 30689735
Drug: Nimotuzumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (200 mg weekly) combined with cisplatin (100 mg/m2 D1) and 5-fluorouracil (4 g/m2 continuous infusion D1-4) every 3 weeks for a maximum of six cycles
Trial: 30689735
Drug: Nimotuzumab (≥2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (≥2400 mg) and ≥4 cycles of PF
Trial: 30689735
Drug: Nimotuzumab-PF chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab-PF chemotherapy
Trial: 30691339
Drug: Prior warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior warfarin treatment with INR <2
Trial: 30691339
Drug: Prior warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior warfarin treatment with INR ≥2
Trial: 30691536
Drug: Enadenotucirev monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enadenotucirev monotherapy
Trial: 30691827
Drug: Ductal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ductal lavage with intraductal infusion of corticosteroids and antimicrobial agents, followed by breast massage for 2 weeks.
Trial: 30692121
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle
Trial: 30693097
Drug: Psychoeducational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational group treatment
Trial: 30696370
Drug: Sufficient iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufficient iodine intake (188 μg/day [145-235 μg/day])
Trial: 30696422
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-testing kit
Trial: 30696669
Drug: Escalation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation of controller therapy during visits
Trial: 30697903
Drug: Ceritinib (second-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceritinib (second-generation ALK inhibitor)
Trial: 30698644
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus lenalidomide (R2); Rituximab 375/m2 i.v. on Day 1; Lenalidomide 20 mg/day (Day 1-21 for cycle 1), 25 mg/day (Day 1-21 for subsequent cycles); followed by maintenance of lenalidomide 10 mg/day for 12 cycles.
Trial: 30700568
Drug: Olaparib 150
RxNorm normalized name: olaparib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 150 mg tablet twice daily combined with metronomic carboplatin AUC2 and paclitaxel 60 mg/m2
Trial: 30700614
Drug: Postdischarge chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdischarge chemotherapy
Trial: 30700726
Drug: Fresh mother's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh mother's own milk once daily from enrollment until 32 weeks' corrected age
Trial: 30703787
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy after high-quality cytoreductive surgery (CRS)
Trial: 30703787
Drug: Hyperthermic intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
Trial: 30703787
Drug: NCT03026140 study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NCT03026140 study on neoadjuvant treatment for early tumors
Trial: 30703787
Drug: New targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New targeted drugs (Eltanexor and cobimetinib)
Trial: 30704447
Drug: Push mechanisms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push mechanisms (e.g. poor health, poor working environment, age discrimination)
Trial: 30704447
Drug: Stay mechanisms
RxNorm normalized name: benzalkonium chloride Topical Foam [Stay Clean]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stay mechanisms (e.g. attractive working conditions, good working environment)
Trial: 30705758
Drug: Radiprodil oral
RxNorm normalized name: Radiprodil
DrugBank: Radiprodil (DB12260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiprodil oral suspension (30 mg, 12 mL)
Trial: 30706431
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DMF) with GI management strategies